Stock comparison
CorMedix
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CRMD
CorMedix
Market cap
$626.05M
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CRMD | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 79B | HALO |
| Benjamin Graham | 38D | 83A | HALO |
| Philip Fisher | 64C | 65B | HALO |
| Peter Lynch | 64C | 53D | CRMD |
| Joel Greenblatt | 48D | 40D | CRMD |
| Charlie Munger | 67D | 80C | HALO |
| Terry Smith | 71B | 84A | HALO |
Side-by-side metrics
| Metric | CRMD | HALO |
|---|---|---|
| Market cap | $626.05M | $8.1B |
| P/E (TTM) | 3.3x | 24.0x |
| EV/EBIT | 3.7x | 10.2x |
| ROIC (TTM) | 27.59% | 23.65% |
| Gross margin | 85.83% | 81.24% |
| Net margin | 45.25% | 23.13% |
| Revenue CAGR 5y | 5.36% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.3x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CRMD leads on
- Revenue CAGR 5y5.36%vs 33.23%+94%
- P/E (TTM)3.3xvs 24.0x+86%
- Debt / Equity0.3xvs 1.0x+65%
- EV/EBIT3.7xvs 10.2x+63%
HALO leads on
- Market cap$8.1Bvs $626.05M+92%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.